Sees FY25 product revenue EUR 683M.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma announces $120M share repurchase program
- Ascendis Pharma: TransCon CNP/hGH Combo Data De-Risk Achondroplasia Program and Support Higher Target Price and Buy Rating
- Ascendis Pharma price target raised to $322 from $297 at Wells Fargo
- Ascendis Pharma Posts Strong Year-Long Phase 2 COACH Data for TransCon CNP and hGH Combo in Achondroplasia
- Ascendis Pharma: Advancing Achondroplasia Combo Franchise and De-Risked Regulatory Path Support Buy Rating and $242 Target